<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="10.1038/ncomms11320 : Article A human genome-wide loss-of-function screen identifies effective" exact="chikungunya" post="antiviral drugs KarlasAlexander12*BerreStefano34*CoudercThérèse34VarjakMargus5BraunPeter12MeyerMichael2GangneuxNicolas34Karo-AstoverLiis5WeegeFriderike1RafteryMartin6SchönrichGünther6KlemmUwe7WurzlbauerAnne8BracherFranz8MeritsAndres5MeyerThomas F.a12†LecuitMarcb349†[1], Max Planck Institute for Infection"/>
 <result pre="effective chikungunya antiviral drugs KarlasAlexander12*BerreStefano34*CoudercThérèse34VarjakMargus5BraunPeter12MeyerMichael2GangneuxNicolas34Karo-AstoverLiis5WeegeFriderike1RafteryMartin6SchönrichGünther6KlemmUwe7WurzlbauerAnne8BracherFranz8MeritsAndres5MeyerThomas F.a12†LecuitMarcb349†[1], Max Planck Institute for" exact="Infection" post="Biology, Department of Molecular BiologyGermany[2], Steinbeis Innovation gGmbH, Center"/>
 <result pre="Innovation gGmbH, Center for Systems BiomedicineGermany[3], Institut Pasteur, Biology of" exact="Infection" post="UnitFrance[4], Inserm U1117France[5], Institute of Technology, University of TartuEstonia[6],"/>
 <result pre="Institute of Virology, Charité University MedicineGermany[7], Max Planck Institute for" exact="Infection" post="Biology, Core Facility Experimental AnimalsGermany[8], Ludwig-Maximilians-University, Department of Pharmacy-Center"/>
 <result pre="Drug ResearchGermany[9], Paris Descartes University, Sorbonne Paris Cité, Division of" exact="Infectious" post="Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Institut"/>
 <result pre="ResearchGermany[9], Paris Descartes University, Sorbonne Paris Cité, Division of Infectious" exact="Diseases" post="and Tropical Medicine, Necker-Enfants Malades University Hospital, Institut ImagineFrance"/>
 <result pre="identified inhibitors have prophylactic antiviral effects in mouse models of" exact="chikungunya" post="infection. Two of them, the calmodulin inhibitor pimozide and"/>
 <result pre="perform a host genome-wide loss-of-function screen to identify targets for" exact="chikungunya" post="antiviral drugs and validate hits using a mouse model"/>
 <result pre="antiviral drugs and validate hits using a mouse model of" exact="chikungunya" post="infection. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that"/>
 <result pre="infection. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes" exact="chikungunya" post="fever, an acute infection characterized by arthralgia and frequently"/>
 <result pre="(CHIKV) is a mosquito-borne alphavirus that causes chikungunya fever, an" exact="acute" post="infection characterized by arthralgia and frequently complicated by chronic"/>
 <result pre="is a mosquito-borne alphavirus that causes chikungunya fever, an acute" exact="infection" post="characterized by arthralgia and frequently complicated by chronic joint"/>
 <result pre="an acute infection characterized by arthralgia and frequently complicated by" exact="chronic" post="joint symptoms1. Originating from Africa, CHIKV has spread to"/>
 <result pre="economic impact, little is known about the cell biology of" exact="CHIKV infection" post="and, as for all emerging infections, neither prophylactic nor"/>
 <result pre="impact, little is known about the cell biology of CHIKV" exact="infection" post="and, as for all emerging infections, neither prophylactic nor"/>
 <result pre="nor therapeutic strategies are available on the market1. In the" exact="absence of" post="available therapeutics and vaccines, there is an urgent need"/>
 <result pre="by the latest generation of drugs available to treat human" exact="immunodeficiency" post="virus (HIV)-infected or hepatitis C virus (HCV)-infected patients, deciphering"/>
 <result pre="of drugs available to treat human immunodeficiency virus (HIV)-infected or" exact="hepatitis" post="C virus (HCV)-infected patients, deciphering that the biology of"/>
 <result pre="hepatitis C virus (HCV)-infected patients, deciphering that the biology of" exact="infections" post="has proven successful for the development of highly effective"/>
 <result pre="successful for the development of highly effective drugs targeting different" exact="viral" post="proteins34. However, this virus-directed strategy for drug discovery is"/>
 <result pre="the context of emerging infections, targeting host factors critical to" exact="infection" post="is a promising approach567. Indeed, this host-directed antiviral design"/>
 <result pre="cells. We analyse the cellular pathways and factors necessary for" exact="CHIKV infection" post="and identify antiviral drugs with both in vitro and"/>
 <result pre="We analyse the cellular pathways and factors necessary for CHIKV" exact="infection" post="and identify antiviral drugs with both in vitro and"/>
 <result pre="was performed by reversely transfecting a genome-wide library of ∼60,000" exact="short" post="interfering RNAs (siRNAs) targeting ∼17,000 annotated and ∼6,000 predicted"/>
 <result pre="fluorescent protein (GFP) (CHIKV-GFP) in infected cells. At 18 h post" exact="infection" post="(p.i.), cells were fixed and analysed by automatic fluorescence"/>
 <result pre="and normalized using as positive control, an siRNA targeting the" exact="viral" post="E1 gene, and as negative control AllStars siRNA (Supplementary"/>
 <result pre="(DENV)20, West Nile virus (WNV)21, HIV-1 (refs 13, 22) or" exact="vaccinia" post="virus (VACV)23 (Fig. 1c; see Supplementary Data 3 for"/>
 <result pre="used a CHIKV replicon, allowing measurement of genomic and subgenomic" exact="viral" post="RNA (vRNA) expression simultaneously (Supplementary Fig. 3a). Consistent with"/>
 <result pre="these hits on the replication of a wide spectrum of" exact="viral" post="species. Cells were treated with specific inhibitors of fatty"/>
 <result pre="acid synthesis, calmodulin signalling, FLT4 and vATPase, and infected with" exact="cytosolic" post="double-stranded DNA virus (cowpox, CPXV), nuclear double-stranded DNA virus"/>
 <result pre="DNA virus (cowpox, CPXV), nuclear double-stranded DNA virus (herpes simplex" exact="type 1," post="HSV-1, or adenovirus type 5, Ad5) or negative-stranded segmented"/>
 <result pre="double-stranded DNA virus (herpes simplex type 1, HSV-1, or adenovirus" exact="type 5," post="Ad5) or negative-stranded segmented RNA virus (IAV) (Fig. 4)."/>
 <result pre="in the antiviral activity of these compounds were observed between" exact="viral" post="species, suggesting that the identified cellular pathways are required"/>
 <result pre="the identified antiviral compounds, we investigated which stage of the" exact="viral" post="life cycle was affected by inhibition of each of"/>
 <result pre="distinct druggable targets. In a first set of experiments, single-cycle" exact="CHIKV infection" post="was measured before or after viral entry (Fig. 5a)."/>
 <result pre="druggable targets. In a first set of experiments, single-cycle CHIKV" exact="infection" post="was measured before or after viral entry (Fig. 5a)."/>
 <result pre="of experiments, single-cycle CHIKV infection was measured before or after" exact="viral" post="entry (Fig. 5a). Infectivity of the supernatants of post-entry-treated"/>
 <result pre="specificity control for this pathway (Fig. 5e). Because of the" exact="incomplete" post="inhibition observed with the CLK1 inhibitor KH-CB19 at early"/>
 <result pre="we were not able to precisely determine the step of" exact="infection" post="controlled by CLK1 (Supplementary Fig. 5a). Importantly, consistent with"/>
 <result pre="inhibitors significantly reduced vRNA synthesis (Fig. 5h) and strongly inhibited" exact="viral" post="release in the supernatants (Fig. 5i), with no detectable"/>
 <result pre="no detectable cell toxicity (Fig. 5j) when applied following 1-h" exact="infection" post="with wild-type CHIKV isolate C21. Of note, a delayed"/>
 <result pre="impact on vRNA replication but induced a major defect in" exact="viral" post="release (Fig. 5k,l), suggesting that the pathways targeted by"/>
 <result pre="6f,g; P=0.0133, two-sided t-test). Tivozanib treatment also significantly reduced CHIKV" exact="viral" post="load in different vital organs (Fig. 6h). Finally, we"/>
 <result pre="on mouse growth and were therefore not used further in" exact="neonatal" post="mice, but tested in the adult mouse footpad injection"/>
 <result pre="not used further in neonatal mice, but tested in the" exact="adult" post="mouse footpad injection model363738. Mice were pretreated for at"/>
 <result pre="demonstrated an antiviral effect in the same mouse model of" exact="CHIKV infection." post="We initially tested the effect of drugs administrated in"/>
 <result pre="monotherapy, TOFA and pimozide combination resulted in increased inhibition of" exact="CHIKV infection" post="rate (5 μM each, interaction effect=0.44; lower=0.36; upper=0.54; P&amp;lt;0.001, two-factor"/>
 <result pre="TOFA and pimozide combination resulted in increased inhibition of CHIKV" exact="infection" post="rate (5 μM each, interaction effect=0.44; lower=0.36; upper=0.54; P&amp;lt;0.001, two-factor"/>
 <result pre="evaluated the anti-CHIKV effect of drug combination in vivo, in" exact="adult" post="mice therapeutically treated with pimozide and TOFA alone or"/>
 <result pre="effect=0.16; lower=0.05; upper=0.47; P&amp;lt;0.001, two-factor design method) and in CHIKV-induced" exact="joint swelling" post="(Fig. 7e) (interaction effect=0.94; lower=0.79; upper=1.13; P=0.506, two-factor design"/>
 <result pre="upper=1.13; P=0.506, two-factor design method), when therapeutically administrated to infected" exact="adult" post="mice, suggesting that combining different drugs identified in the"/>
 <result pre="the Americas, still little is known regarding CHIKV cell biology." exact="CHIKV infection" post="in human is associated with acute and chronic symptoms,"/>
 <result pre="Americas, still little is known regarding CHIKV cell biology. CHIKV" exact="infection" post="in human is associated with acute and chronic symptoms,"/>
 <result pre="CHIKV cell biology. CHIKV infection in human is associated with" exact="acute" post="and chronic symptoms, which pathophysiology remains incompletely understood, and"/>
 <result pre="biology. CHIKV infection in human is associated with acute and" exact="chronic" post="symptoms, which pathophysiology remains incompletely understood, and there is"/>
 <result pre="functions required for multiple steps of CHIKV life cycle, from" exact="viral" post="entry, replication to viral release. For example, we demonstrated"/>
 <result pre="steps of CHIKV life cycle, from viral entry, replication to" exact="viral" post="release. For example, we demonstrated the critical role of"/>
 <result pre="we demonstrated the critical role of the vacuolar ATPase in" exact="viral" post="entry, and lipid biosynthesis in vRNA replication and release."/>
 <result pre="interest for antiviral drug discovery in the field of emerging" exact="infectious diseases." post="Importantly, most of the identified proviral hits and all"/>
 <result pre="are also critical for the replication of other very diverse" exact="viral" post="species (including IAV, SINV, HIV-1 and HCV; see Fig."/>
 <result pre="well as in vivo, although it did not completely block" exact="viral" post="replication in this setting. Additional studies will be required"/>
 <result pre="screening, the drug screening and the drugs testing on different" exact="viral" post="species were cultured in DMEM (Life Technologies 31966-047) supplemented"/>
 <result pre="100 U ml−1 penicillin/streptomycin (Life Technologies 15140-122) and 10% FCS. Human lung" exact="epithelial" post="A549 cells (CCL-185, ATCC-LGC) were cultured in DMEM supplemented"/>
 <result pre="and 5% FCS for cell passaging and 2% FCS for" exact="viral" post="titration with the TCID50 assay. C6/36 cells (CRL-1573, ATCC-LGC)"/>
 <result pre="SINV AR339 (both kind gifts of P. Desprès, Paris, France)." exact="Viral" post="production and titration were performed as previously detailed40. Briefly,"/>
 <result pre="using Vivaspin concentrators (molecular weight cut off (MWCO) 100,000 kDa, Sartorius)." exact="Viral" post="titration of cell supernatants (Fig. 7b) was performed by"/>
 <result pre="replicon vector expressing only Fluc under the subgenomic promoter. Chikungunya" exact="viral" post="replicon particles (VRPs) were produced using the split-helper system"/>
 <result pre="titre VRPs. GFP-expressing recombinant viruses used in Fig. 4 were" exact="cowpox" post="virus strain Brighton Red vBRFseR (CPXV; provided by K."/>
 <result pre="vBRFseR (CPXV; provided by K. Tischer, Freie Universität Berlin, Germany)," exact="herpes" post="simplex virus 1 strain KOS K26GFP (HSV-1; provided by"/>
 <result pre="steps followed by dialysis and freezing at −80 °C until use." exact="Viral" post="titre of the frozen stocks was determined by both"/>
 <result pre="was determined by both GFP expression at 1 day post" exact="infection" post="and plaque formation at 7 days post infection of"/>
 <result pre="day post infection and plaque formation at 7 days post" exact="infection" post="of Vero E6 or HEK-293 cells. Virus stocks were"/>
 <result pre="used for the screening because of their concomitant permissiveness to" exact="CHIKV infection" post="and to high-efficiency siRNA transfection. Transfections of siRNAs in"/>
 <result pre="for the screening because of their concomitant permissiveness to CHIKV" exact="infection" post="and to high-efficiency siRNA transfection. Transfections of siRNAs in"/>
 <result pre="were incubated at 37 °C and 5% CO2 for 72 h before" exact="infection" post="with 3.5 × 104 plaque-forming units (PFUs). At 18 h"/>
 <result pre="post infection, cells were fixed and nuclei stained with Hoechst." exact="Infection" post="protocol was set-up to reach ∼50% of infected cells"/>
 <result pre="same transfection and screening conditions were used as in the" exact="primary" post="screen. Microarray analysis To allow exclusion of non-expressed genes"/>
 <result pre="carried out by adding 4 × 105 HEK-293 cells (in" exact="complete" post="DMEM medium) to a mixture of serum-free RPMI medium,"/>
 <result pre="medium, HiPerFect (Qiagen) and AllStars siRNAs (final siRNA concentration: 20 nM)." exact="Infection" post="with CHIKV-GFP was performed 72 h post transfection at a"/>
 <result pre="CHIKV-GFP was performed 72 h post transfection at a multiplicity of" exact="infection" post="(MOI) of 3. Cells were lysed 18 h p.i. using"/>
 <result pre="electrophoresis, transferred to nitrocellulose membrane (GE Lifesciences) and detected using" exact="primary" post="antibodies against ACC (clone EP687Y, from Abcam, ab45174, 1:1,000),"/>
 <result pre="(clone C4, Santa Cruz Biotechnology, sc-47778, 1:2,000). Appropriate horseradish peroxidase-conjugated" exact="secondary" post="antibodies (LabAs Ltd) were used for visualization. Enhanced chemiluminescence"/>
 <result pre="Antibodies were diluted in PBS containing 5% FCS. The following" exact="primary" post="antibodies were used: rabbit anti-ACC (clone EP687Y, from Abcam,"/>
 <result pre="(clone J2, English and Scientific Consulting Kft, 1:200); incubation with" exact="primary" post="antibodies was followed by treatment with secondary antibodies: anti-rabbit"/>
 <result pre="1:200); incubation with primary antibodies was followed by treatment with" exact="secondary" post="antibodies: anti-rabbit antibodies conjugated with Alexa Fluor 488 and"/>
 <result pre="anti-rabbit antibodies conjugated with Alexa Fluor 488 were used as" exact="secondary" post="antibodies. HeLa cells were transfected for 20 h (using the"/>
 <result pre="various substances in eight different 1:3 dilutions 2 h before infection." exact="Infection" post="was performed using 3.5 × 104 PFU CHIKV-GFP per"/>
 <result pre="multi-well pipetting steps were performed as described above. To analyse" exact="primary" post="infection of herpes simplex type 1 strain KOS (HSV-1),"/>
 <result pre="pipetting steps were performed as described above. To analyse primary" exact="infection" post="of herpes simplex type 1 strain KOS (HSV-1), cowpox"/>
 <result pre="were performed as described above. To analyse primary infection of" exact="herpes" post="simplex type 1 strain KOS (HSV-1), cowpox strain Brighton"/>
 <result pre="as described above. To analyse primary infection of herpes simplex" exact="type 1" post="strain KOS (HSV-1), cowpox strain Brighton Red (CPXV) or"/>
 <result pre="primary infection of herpes simplex type 1 strain KOS (HSV-1)," exact="cowpox" post="strain Brighton Red (CPXV) or adenovirus strain 5 (Ad5),"/>
 <result pre="test the antiviral efficacy against IAV/WSN/33 (IAV) viruses. Human lung" exact="epithelial" post="A549 cells were pretreated with small molecules for 2 h"/>
 <result pre="and then inoculated with WSN at MOI 0.02. After 40 min," exact="infection" post="medium (DMEM supplemented with 0.2% BSA, 4 mM L-glutamine, antibiotics"/>
 <result pre="cells were cultivated for 6 h under normal culture conditions with" exact="infection" post="medium. Cells were stained for viral NP protein and"/>
 <result pre="normal culture conditions with infection medium. Cells were stained for" exact="viral" post="NP protein and nuclei, and the infection rate (that"/>
 <result pre="were stained for viral NP protein and nuclei, and the" exact="infection" post="rate (that is, the rate of NP-positive cells) was"/>
 <result pre="stock; all from Sigma). To determine the step of the" exact="viral" post="cycle affected by chemical compounds, HEK-293T cells (seeded the"/>
 <result pre="plates) were either treated 2 h before or 2 h after cell" exact="infection" post="with CHIKV C21 (MOI 40) and left until 8 h"/>
 <result pre="with CHIKV C21 (MOI 40) and left until 8 h p.i." exact="Viral infection" post="was quantified by flow cytometry measurement of the %"/>
 <result pre="CHIKV C21 (MOI 40) and left until 8 h p.i. Viral" exact="infection" post="was quantified by flow cytometry measurement of the %"/>
 <result pre="from the 2 h post treatment conditions were then measured for" exact="viral" post="infectivity on Vero cells (final volume: 150 μl). The percentage"/>
 <result pre="analysis, we took advantage of the high-precision measurement of the" exact="acquired" post="volumes made by the MACSQuant VYB cytometers. Then, knowing"/>
 <result pre="VYB cytometers. Then, knowing the initial volume of cells, the" exact="acquired" post="volume and the acquired number of events, we estimated"/>
 <result pre="the initial volume of cells, the acquired volume and the" exact="acquired" post="number of events, we estimated the total number of"/>
 <result pre="volume and the acquired number of events, we estimated the" exact="total" post="number of cells per well. Cell staining for these"/>
 <result pre="and flow cytometry For vRNA quantification, vRNA was extracted from" exact="infection" post="supernatants using the QIAamp Viral RNA Mini Kit (Qiagen),"/>
 <result pre="quantification, vRNA was extracted from infection supernatants using the QIAamp" exact="Viral" post="RNA Mini Kit (Qiagen), whereas total RNA from cells"/>
 <result pre="supernatants using the QIAamp Viral RNA Mini Kit (Qiagen), whereas" exact="total" post="RNA from cells was extracted using the RNeasy Mini"/>
 <result pre="the 2−ΔΔCT method, whereas a standard curve derived from a" exact="viral" post="stock of known titre was used to quantify vRNA"/>
 <result pre="the analysis. The percentage of infected cells was used as" exact="infection" post="readout. Data were then normalized by setting the DMSO"/>
 <result pre="methanol for 20 min and stained in permeabilization buffer. Cells were" exact="acquired" post="using an LSR-fortessa flow cytometer (BD). Anti-mouse IgG antibodies"/>
 <result pre="Alexa Fluor 647 (both from Life Technologies) were used as" exact="secondary" post="antibodies. We used cells stained with a mouse isotype"/>
 <result pre="(clone MOPC-21, Biolegend, 400101, 1:50) or with the anti-rabbit IgG" exact="secondary" post="antibody only as labelling controls. In vivo experiments All"/>
 <result pre="Committee on 17 October 2014. Two different mouse models of" exact="CHIKV infection" post="were used for our studies: (i) the intradermal infection"/>
 <result pre="on 17 October 2014. Two different mouse models of CHIKV" exact="infection" post="were used for our studies: (i) the intradermal infection"/>
 <result pre="CHIKV infection were used for our studies: (i) the intradermal" exact="infection" post="model of neonatal mice, characterized by CHIKV dissemination through"/>
 <result pre="used for our studies: (i) the intradermal infection model of" exact="neonatal" post="mice, characterized by CHIKV dissemination through the bloodstream, replication"/>
 <result pre="joints) and association with paralysis and death32; (ii) the footpad" exact="infection" post="model, characterized by a rapid local replication of CHIKV"/>
 <result pre="a rapid local replication of CHIKV at the site of" exact="infection" post="and by the induction of inflammation and footpad swelling363738."/>
 <result pre="the induction of inflammation and footpad swelling363738. Both male and" exact="female" post="mice were used for experiments in Fig. 6. Experiments"/>
 <result pre="in Fig. 6. Experiments in Fig. 7 were conducted on" exact="female" post="mice. Clk1 conditional knockout mice (C57BL/6NTac-Clk /Ics) were purchased"/>
 <result pre="subcutaneously infected with CHIKV C21 in the footpad (103 PFU)." exact="Mouse" post="health status and body weight were scored daily. Drugs"/>
 <result pre="using a Precellys 24 homogenizer (Bertin Technologies). In Fig. 7e," exact="joint swelling" post="was measured 4 days p.i. using a Schnelltaster caliper."/>
 <result pre="a Schnelltaster caliper. Data analysis and reproducibility For identification of" exact="primary" post="hits, mainly the inhibitory effect on CHIKV, replication was"/>
 <result pre="filtered out). (ii) Using the microscopic assay applied throughout the" exact="primary" post="screen, toxic siRNAs, which reduced total cell numbers (&amp;lt;1,000"/>
 <result pre="assay applied throughout the primary screen, toxic siRNAs, which reduced" exact="total" post="cell numbers (&amp;lt;1,000 cells per well) on transfection were"/>
 <result pre="at least three independent replicates were used for RSA analysis16." exact="Primary" post="hits were selected by using the cutoff criterion log"/>
 <result pre="criterion log P≤2. The validation was performed based on the" exact="primary" post="hit list, thereby focusing not only on proviral but"/>
 <result pre="antiviral factors. Although the validation was experimentally identical to the" exact="primary" post="screening, the hit selection varied slightly: after filtering out"/>
 <result pre="A. et al. A human genome-wide loss-of-function screen identifies effective" exact="chikungunya" post="antiviral drugs. Nat. Commun. 7:11320 doi: 10.1038/ncomms11320 (2016). Supplementary"/>
 <result pre="genes in common between our and other RNAi screens for" exact="viral" post="host factors. LINK Supplementary Data 4 Sequences of the"/>
 <result pre="J. Med.372, 1231–1239 (2015).25806915 BekermanE. &amp;amp; EinavS.Infectious disease. Combating emerging" exact="viral" post="threats. Science348, 282–283 (2015).25883340 De ClercqE.The design of drugs"/>
 <result pre="Drug Discov.6, 1001–1018 (2007).18049474 ScheelT. K. &amp;amp; RiceC. M.Understanding the" exact="hepatitis" post="C virus life cycle paves the way for highly"/>
 <result pre="LanfordR. E.et al.. Therapeutic silencing of microRNA-122 in primates with" exact="chronic hepatitis" post="C virus infection. Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing"/>
 <result pre="E.et al.. Therapeutic silencing of microRNA-122 in primates with chronic" exact="hepatitis" post="C virus infection. Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing"/>
 <result pre="Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C" exact="virus infection." post="Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing a viral infection"/>
 <result pre="C virus infection. Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing a" exact="viral infection" post="by targeting the host: the example of cyclophilin inhibitors."/>
 <result pre="virus infection. Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing a viral" exact="infection" post="by targeting the host: the example of cyclophilin inhibitors."/>
 <result pre="(2013).24034620 BrassA. L.et al.. Identification of host proteins required for" exact="HIV infection" post="through a functional genomic screen. Science319, 921–926 (2008).18187620 KonigR.et"/>
 <result pre="BrassA. L.et al.. Identification of host proteins required for HIV" exact="infection" post="through a functional genomic screen. Science319, 921–926 (2008).18187620 KonigR.et"/>
 <result pre="W.et al.. A functional genomic screen identifies cellular cofactors of" exact="hepatitis" post="C virus replication. Cell Host Microbe5, 298–307 (2009).19286138 LiQ.et"/>
 <result pre="Host Microbe5, 298–307 (2009).19286138 LiQ.et al.. Integrative functional genomics of" exact="hepatitis" post="C virus infection identifies host dependencies in complete viral"/>
 <result pre="298–307 (2009).19286138 LiQ.et al.. Integrative functional genomics of hepatitis C" exact="virus infection" post="identifies host dependencies in complete viral replication cycle. PLoS"/>
 <result pre="(2009).19286138 LiQ.et al.. Integrative functional genomics of hepatitis C virus" exact="infection" post="identifies host dependencies in complete viral replication cycle. PLoS"/>
 <result pre="genomics of hepatitis C virus infection identifies host dependencies in" exact="complete" post="viral replication cycle. PLoS Pathog.10, e1004163 (2014).24852294 SessionsO. M.et"/>
 <result pre="of hepatitis C virus infection identifies host dependencies in complete" exact="viral" post="replication cycle. PLoS Pathog.10, e1004163 (2014).24852294 SessionsO. M.et al.."/>
 <result pre="RNA interference screen for human genes associated with West Nile" exact="virus infection." post="Nature455, 242–245 (2008).18690214 KonigR.et al.. Global analysis of host-pathogen"/>
 <result pre="Proc. Natl Acad. Sci. USA110, 3519–3524 (2013).23401514 HeatonN. S.et al.." exact="Dengue" post="virus nonstructural protein 3 redistributes fatty acid synthase to"/>
 <result pre="nonstructural protein 3 redistributes fatty acid synthase to sites of" exact="viral" post="replication and increases cellular fatty acid synthesis. Proc. Natl"/>
 <result pre="Nucleic Acids Res.40, D1100–D1107 (2012).21948594 SourisseauM.et al.. Characterization of reemerging" exact="chikungunya" post="virus. PLoS Pathog.3, e89 (2007).17604450 YasunagaA.et al.. Genome-wide RNAi"/>
 <result pre="al.. The STAT5 inhibitor pimozide displays efficacy in models of" exact="acute" post="myelogenous leukemia driven by FLT3 mutations. Genes Cancer3, 503–511"/>
 <result pre="STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous" exact="leukemia" post="driven by FLT3 mutations. Genes Cancer3, 503–511 (2012).23264850 KangS.,"/>
 <result pre="Res.112, 125–133 (2013).23701975 ZieglerS. A.et al.. In vivo imaging of" exact="chikungunya" post="virus in mice and Aedes mosquitoes using a Renilla"/>
 <result pre="Dis.11, 1471–1477 (2011).21668347 MorrisonT. E.et al.. A mouse model of" exact="chikungunya" post="virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
 <result pre="H.et al.. A pathogenic role for CD4+ T cells during" exact="Chikungunya virus infection" post="in mice. J. Immunol.190, 259–269 (2013).23209328 VanlandinghamD. L.et al.."/>
 <result pre="al.. A pathogenic role for CD4+ T cells during Chikungunya" exact="virus infection" post="in mice. J. Immunol.190, 259–269 (2013).23209328 VanlandinghamD. L.et al.."/>
 <result pre="A pathogenic role for CD4+ T cells during Chikungunya virus" exact="infection" post="in mice. J. Immunol.190, 259–269 (2013).23209328 VanlandinghamD. L.et al.."/>
 <result pre="VanlandinghamD. L.et al.. Development and characterization of a double subgenomic" exact="chikungunya" post="virus infectious clone to express heterologous genes in Aedes"/>
 <result pre="al.. Development and characterization of a double subgenomic chikungunya virus" exact="infectious" post="clone to express heterologous genes in Aedes aegypti mosquitoes."/>
 <result pre="Mol. Biol.35, 1162–1170 (2005).16102421 CoudercT.et al.. Prophylaxis and therapy for" exact="Chikungunya virus infection." post="J. Infect. Dis.200, 516–523 (2009).19572805 GlaskerS.et al.. Virus replicon"/>
 <result pre="Biol.35, 1162–1170 (2005).16102421 CoudercT.et al.. Prophylaxis and therapy for Chikungunya" exact="virus infection." post="J. Infect. Dis.200, 516–523 (2009).19572805 GlaskerS.et al.. Virus replicon"/>
 <result pre="validation and data analysis: A.K. and M.M. CHIKV in vitro" exact="infection" post="and replication assays were performed by A.K., S.B., N.G."/>
 <result pre="were performed by A.K., S.B., N.G. and T.C. In vitro" exact="infection" post="and replication assays for all other viruses were performed"/>
 <result pre="M.L. analysed the data and wrote the manuscript. Figure 1" exact="Primary" post="screen for CHIKV host cell factors. (a) Outline of"/>
 <result pre="(n=9). (e) Validation of CLK1 as CHIKV relevant host factor." exact="Infection" post="rate of A549 cells depleted for CLK1 by CRISPR/Cas9"/>
 <result pre="CHIKV replication. Closed and open symbols indicate replicates from the" exact="primary" post="screen and during validation, respectively. (b) Western blot showing"/>
 <result pre="indicate the corresponding dose–response curves determined for cell viability and" exact="CHIKV infection," post="respectively (Table 1; Supplementary Fig. 4). Data were obtained"/>
 <result pre="vitro validation of selected chemical inhibitors and proviral factors. (a–g)" exact="Infection" post="rate and cell viability for compounds specific to vATPase"/>
 <result pre="treated 2 h before (solid lines) or 2 h after (dashed lines)" exact="infection" post="with CHIKV C21 (MOI 40) and left until 8 h"/>
 <result pre="left until 8 h p.i. to avoid multiple cycles of infection." exact="Viral" post="infectivity and cell viability were then measured by flow"/>
 <result pre="supernatants from the 2 h post treatment conditions were measured for" exact="viral" post="infectivity on Vero cells (dotted lines) to detect eventual"/>
 <result pre="on Vero cells (dotted lines) to detect eventual defects in" exact="viral" post="release. (h,i) Quantitative PCR with reverse transcription quantification of"/>
 <result pre="the appearance of paralysis. (c) Experimental design of the intradermal" exact="infection" post="of the young mouse model used for tivozanib. (d–f)"/>
 <result pre="measuring the area under the body weight curve. (h) CHIKV" exact="viral" post="load measured 3 days post infection in the indicated"/>
 <result pre="weight curve. (h) CHIKV viral load measured 3 days post" exact="infection" post="in the indicated organs obtained from mice treated with"/>
 <result pre="for all data sets). (i,j) Experimental design of the footpad" exact="infection" post="of adult mice model used and viral titres measured"/>
 <result pre="data sets). (i,j) Experimental design of the footpad infection of" exact="adult" post="mice model used and viral titres measured in C57BL/6"/>
 <result pre="of the footpad infection of adult mice model used and" exact="viral" post="titres measured in C57BL/6 mice treated with pimozide (pimo,"/>
 <result pre="n=11 for both data sets) or the corresponding vehicles before" exact="infection" post="with CHIKV C21 (103 PFU). Data in b,f and"/>
 <result pre="combination on CHIKV replication in vitro and in vivo. (a–c)" exact="Infection" post="rate (n=9 for all data sets at increasing concentrations;"/>
 <result pre="measured by flow cytometry. (d) Experimental design of the footpad" exact="CHIKV infection" post="model of adult mice used to measure the therapeutic"/>
 <result pre="by flow cytometry. (d) Experimental design of the footpad CHIKV" exact="infection" post="model of adult mice used to measure the therapeutic"/>
 <result pre="(d) Experimental design of the footpad CHIKV infection model of" exact="adult" post="mice used to measure the therapeutic effect on CHIKV"/>
 <result pre="considered for statistics). (e) Footpad swelling measured 4 days post" exact="infection" post="in mice treated as in d (n=11, 10, 12"/>
 <result pre="Sorafenib 1.11 18.24 16.42 Linifanib 2.15 &amp;gt; 60 NT CHIKV," exact="chikungunya" post="virus; CLK1, CDC-like kinase 1; FLT4, fms-related tyrosine kinase"/>
 <result pre="inhibiting CHIKV replication and their respective molecular targets or pathways." exact="CHIKV infection" post="and cell viability (WST-1) was measured in cells pretreated"/>
 <result pre="CHIKV replication and their respective molecular targets or pathways. CHIKV" exact="infection" post="and cell viability (WST-1) was measured in cells pretreated"/>
</results>
